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Abstract 
 
Topical protoporphyrin (PpIX)-induced photodynamic therapy (PDT) relies on the 
penetration of the prodrug into the skin lesion and subsequent accumulation of the 
photosensitiser.  Methyl aminolevulinate (MAL)-PDT is an established treatment for thinner 
and superficial non-melanoma skin cancers (NMSC) but for the treatment of the thicker 
nodular basal cell carcinoma (nBCC) enhanced penetration of the prodrug is required.  This 
study employed a new higher pressure, oxygen pressure injection (OPI) device, at the time of 
Metvix® application with a view to enhancing the penetration of MAL into the tumors.  Each 
patient had Metvix® applied to a single nBCC followed by application of a higher pressure 
OPI device.  Following different time intervals (0, 30, 60, 120 or 180 minutes) the tumors 
were excised.  The maximum depth and area of MAL penetration achieved in each lesion was 
measured using PpIX fluorescence microscopy.  As expected, an increase in the depth of 
MAL-induced PpIX accumulation and area of tumor sensitized was observed over time; 
when the Metvix® cream was applied for 0, 30, 60, 120 and 180 minutes the median depth of 
PpIX fluorescence was 0, 21, 26.5, 75.5 and 90%, respectively and the median area of tumor 
sensitized was 0, 4, 6, 19 and 60%, respectively.  As the investigation presented here did not 
include a control arm, the relative depths of fluorescence observed in this study were 
statistically compared (using the non-parametric Mann Whitney U test) with the results of our 
previous study where patients had Metvix® cream applied either with or without the standard 
pressure OPI device.   When the higher pressure OPI device was employed compared to 
without OPI this increase was observed to be greater following 30, 120 & 180 minutes 
although overall not significantly (p=0.835).  In addition, no significant difference between 
the higher pressure OPI device employed here and the previously investigated standard 
pressure OPI device was observed (p=0.403).  However, when the results for both OPI 
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devices were combined and compared to the standard treatment (no OPI employed) group, 
although the difference did not reach significance (p=0.531) a consistent and substantial 
increase in the depth of PpIX fluorescence was observed, therefore employment of an OPI 
device during topical MAL-PDT protocols warrants further investigation as a technique for 
enhancing MAL penetration.   
 
1. Introduction 
 
Basal cell carcinoma (BCC) is by far the most common form of cancer found in 
Caucasians worldwide [1].  In 2008, of the 98,800 people in the UK (a number which is 
thought to be underestimated) diagnosed with a non-melanoma skin cancer (NMSC), 45-50% 
of these were nodular BCC (nBCC) [2].  Although rarely life-threatening if left untreated 
nBCC can cause bleeding and local destruction resulting in disfiguration.  In addition, a very 
small proportion of these tumors may metastasize into surrounding tissues and bones [2] so it 
is essential that all cases are treated.   
Currently, the established treatments preferably undertaken for the treatment of nBCC 
are surgical excision and Moh’s microscopic surgery.  Although effective, these treatment 
modalities result in scarring.  This is particularly undesirable for many nBCC patients with 
lesions on highly visible sites.  In a population-based study it was found, for both genders, 
that the body-site distribution of nBCC was dominated by the face, followed by the neck [3].  
Additionally, a single patient may have multiple nBCCs, and depending on their location 
some patients may require reconstructive surgery following excision.   
Topical PDT offers a non-invasive alternative treatment modality with excellent 
cosmesis [4].  For the treatment of actinic keratosis (AK), Bowen’s disease (BD) and 
superficial BCC (sBCC) PpIX-induced PDT with 5-aminolaevulinic acid (ALA) or methyl 
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aminolevulinate (MAL) has successful and sustained clearance rates [5].  For the treatment of 
nBCC however the topical use of ALA/MAL-PDT is limited by the depth of the therapeutic 
effect the current protocols can achieve as demonstrated by Martin et al. in a clinical trial of 
topical ALA-PDT of BCCs which revealed a highly variable ALA uptake into nodular and 
infiltrating BCC [6].  Past studies have found low cure rates ranging from 10% to 42% when 
ALA-PDT was investigated for the treatment of nBCC [9-12].  ALA is a small molecule 
which when applied topically can diffuse into cutaneous tissue but because it is hydrophilic it 
has limited capacity to cross tissue barriers such as the hydrophobic stratum corneum of the 
skin.  Therefore the ester derivative, MAL, with greater lipophilicity (provided by the 
additional alkyl chain), can be utilised as it is expected to cross the stratum corneum more 
easily than ALA [13].  Past studies by Peng et al. have reported that in lesions of up to 2 mm 
thickness the application of MAL for 3 hours showed the highest ratio of PpIX fluorescence 
depth to tumor depth [7], in contrast to the more limited penetration with ALA [8].  A review 
of the use of MAL-PDT for the treatment of nBCC found clearance rates ranging from 75-
82% at 3 months to 77% at 60 months [14].  Compared to standard surgical excision in a 
study of 101 patients with small nBCC lesions the clearance rate at 12 months were not 
dissimilar between the two treatment groups (surgery; 96% & PDT; 85%).  However, follow 
up data after 5 years recorded recurrence rates to be significantly higher for the MAL-PDT 
treated lesions (14%) versus those surgically excised (4%).  Longer follow-up data is needed 
to support the use of MAL-PDT for the treatment of nBCC versus surgical excision which 
has 5-year recurrence rates of less than 10% [15].   
Successful PDT treatments require sufficient amounts of the photosensitiser, light of 
the correct activating wavelength and adequate tissue oxygen.  Therefore the first 
consideration in topical PDT is the optimum depth of prodrug penetration and subsequent 
photosensitiser production.  Methods of penetration enhancement for topical PpIX-PDT 
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prodrugs have included; the use of chemicals (e.g. DMSO [16] or glycolic acid [17]), 
iontophoresis [18], lesion surface preparation (e.g. gentle curettage [19] or tape-stripping 
[20]), elevating skin temperature [21], pressurized oxygen [22], micro-needle puncture [23], 
nanoemulsions [24] and needleless jet injection [25]. 
A previous study [22] conducted by our group with a (standard pressure) oxygen 
pressure injection (OPI) device recruited 6 patients into each of five study groups (0, 30, 60, 
120 or 180 minutes Metvix® application) with half the nBCC lesions in each group receiving 
standard pressure OPI (a metered dosage of oxygen released at 2.0 bar).  Results showed that 
over time, for all patients, an increase in PpIX fluorescence was observed.  Notably, when the 
standard pressure OPI device was employed, PpIX fluorescence was enhanced relative to the 
standard treatment group which simply had the Metvix® cream applied as per normal 
practice without an OPI device [22].  Following Metvix® application with the standard 
pressure OPI device after 30, 60, 120 and 180 minutes the mean relative depth of PpIX 
fluorescence increased by 25%, 49%, 12% and 16%, respectively compared to the groups 
where the Metvix® cream was applied without OPI.  The study presented here continues this 
investigation utilizing a newly available, higher pressure (2.2 bar) OPI device (Fig. 1) with a 
view to further increasing the penetration of MAL into nBCC lesions.   
   
2. Materials and methods 
 
The protocol and procedures conducted in this clinical trial were approved by the UK 
National Research Ethics Service (NRES).  All patients were given verbal and written 
information regarding the study and all gave their agreement by written informed consent 
prior to the start of the study procedures.  This study was an observer-blinded preliminary 
investigation of a single topical application of Metvix® cream (Galderma, France), 
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containing the photosensitizing prodrug MAL (160 mg/g), to nBCC with an OPI device.  
Fifteen Caucasian patients with a single nBCC lesion requiring treatment by surgical excision 
were recruited into the study.  Three patients were allocated into each of the 5 study groups 
(0, 30, 60, 120 or 180 minutes Metvix® cream application).   
Metvix® cream (1 mm thick) was applied to the nBCC lesion (including a 5 mm 
margin of surrounding normal skin) and lesions were then subjected to the OPI device.  A 
metered dosage of oxygen was released at 2.2 bar through a hose system and a pressure-
reducing valve which exits through a domed shaped nozzle.  The latter was specifically 
designed so that when placed firmly over the lesion minimum oxygen could escape.  This 
higher pressure OPI device (oxygen released at 2.2 bar) and the previously employed 
standard pressure OPI device (oxygen released at 2.0 bar) both work in exactly the same way 
except different oxygen pressures are exerted. The OPI machines work by concentrating 
oxygen from the air and purifying it through a series of filters.  Using two molecular sieve 
chambers the oxygen molecules are separated, resulting in almost pure oxygen which is 
concentrated up to a maximum of 97% [26].  The amount of pressure exerted is not sufficient 
to damage skin and is not painful to the patient.  The button was pressed six times over each 
lesion, with the treatment time for each metered application being 0.1 second.  This arbitrary 
figure was chosen in our previous study [22] to try and ensure maximal effect and was 
therefore used consistently in each case.   Once Metvix® cream is applied to the lesion the 
principle of the OPI device is simply to increase the penetration of the active ingredient MAL 
through the skin under the action of the pulsed pressure of concentrated oxygen. 
 
2.1.      Surgical excision and histology 
All lesions were covered firstly with a sterile dressing (Tegaderm®, 3M) and then with 
a light occlusive dressing (Mepore®).  After 0, 30, 60, 120 or 180 minutes Metvix® 
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application the lesion was removed by elliptical excision by a trained Dermatologist at the 
Royal Cornwall Hospital, Truro, UK.  Tissue samples were immediately transported from the 
Dermatology Department to the Histopathology Department in black light-occluding bags at 
room temperature.  Occluding the tumor from light was an important precaution to avoid 
possible photobleaching of any PpIX present.  In a darkened room the excised tissue was 
measured and cut into sections by a trained Pathologist at the Royal Cornwall Hospital, 
Truro, UK.  One section was taken for normal diagnostic histology and the remaining 
sections were mounted on an appropriate sized cork base with optimal cutting temperature 
(OCT) mounting fluid (Tissue-Tek®, Zoeterwoude, Netherlands) and snap frozen using 
chlorodifluromethane (Cryospray 22, Bright Instruments Co. Ltd., UK).  Frozen sections 
were placed in universal containers and stored in a -80ºC freezer until analysis.   
 
2.2.   Fluorescence microscopy and image analysis 
When all 15 tissue samples had been collected they were removed from storage, coded 
and prepared for cutting as follows.  Each cork embedded tissue was mounted onto a cryostat 
chuck using OCT mounting fluid.  Once equilibrated with the cryostat (OFT5000, Bright 
Instruments Co. Ltd., UK) operating temperature (~-35ºC) 10 µm thick sections were cut 
from the tissue and put onto microscope slides using the Bright 5040 rotary microtome 
(housed in the cryostat).  All microscope slides were kept in the dark during transport to the 
fluorescence microscope.  
The fluorescence microscope (Olympus BX51, Olympus, UK) consisted of; a light 
source and excitation filter to excite the PpIX molecule, an emission filter and camera 
detector (Olympus DP70 CCD, Olympus, UK) to capture the resultant fluorescence and 
finally a computer with analySIS® imaging software to analyze the images.  Appropriate 
filters were previously selected in preliminary in vitro studies, from the absorbance spectra of 
8 
 
0.2 mM pre-synthesized PpIX in DMSO solvent and from the emission spectrum of 10 mM 
pre-synthesized PpIX in DMSO [27].  The XF1008 (405DF40) excitation filter (Omega 
Optical Incorporated, Glen Spectra, UK) was used because it corresponds to the ~407 nm 
Soret absorption band of PpIX and allows the transmission of light between 385 and 425 nm.  
The XF3028 (630DF30) emission filter (Omega Optical Incorporated, Glen Spectra, UK) was 
used because it closely matches the excitation peak of PpIX at ~612 nm having a range of 
615-645 nm.  A dichroic mirror, XF2040 (435DRLP) (Omega Optical Incorporated, Glen 
Spectra, UK) was also used to direct and reflect the emission and excitation wavelengths of 
light [27].  The filters were housed in an Olympus filter holder and placed inside the 
fluorescence microscope.    
Neutral density filters were used to reduce the intensity of the excitation light allowing 
more time to align the sample at a low intensity visible light, prior to capturing the 
fluorescence image which was achieved by choosing the PpIX filter on the microscope.    
During image capture all external light sources were removed and lighting levels were kept to 
a minimum to reduce the effects of photobleaching.  Each tissue sample was analyzed at a 
magnification of x 20 with an exposure time of 10 seconds.   
After the fluorescence images were captured, to demonstrate the architecture of the 
tissue sections each sample was stained using haematoxylin and eosin (H and E).  The 
standard operating procedure to carry out the staining was provided by the Histology 
Department at the Royal Cornwall Hospital (Truro, UK).  Samples were briefly rinsed in 
100% alcohol, rinsed in xylene, taken back to alcohol and washed in distilled water.  They 
were then stained in Mayer’s haematoxylin (20 seconds), washed in distilled water, stained 
blue with Scott’s tap water substitute, washed in distilled water, rinsed in 1% alcohol, rinsed 
in 100% alcohol, stained in alcoholic eosin, rinsed and dehydrated in 100% alcohol, cleared 
with xylene and finally, mounted using Mowiol mounting medium containing 2.5% 1,4-
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diazobicyclo-[2.2.2]-octane (DABCO, Sigma-Aldrich, UK) and a glass coverslip.  These 
samples were then imaged by using unfiltered visible light and the automatic settings of the 
analysis® software control panel (exposure time <1 second).     
 
2.3.   Data analysis 
All the images were exported and analyzed in NIH ImageJ software 
(http://rsb.info.nih.gov/ij/).  For each fluorescence image a precise distance of the maximal 
depth of fluorescence, perpendicular from the surface epithelium was measured.  The 
corresponding H and E slides were all shown independently to a single histological expert 
(blinded to the treatment group) at Royal Cornwall Hospital, Truro, UK to advise on the 
tissue architecture for each section and to confirm the maximal tumor depth.  Precise 
distances of the maximal tumor depth for each tissue sample were then measured.  The 
maximal depth of fluorescence and corresponding maximal tumor depth measurements were 
used to calculate a percentage of depth of PpIX penetration.  In addition, for each 
fluorescence image a measurement of the area of fluorescence was recorded and the area of 
tumor present, as observed from the corresponding H and E slide, was also recorded, thus 
allowing a percentage of PpIX accumulation in relation to the tumor size to be calculated for 
each tissue sample.   
Due to the small sample size (n=3) at each intervention these data are presented as 
medians.  Least squares linear regression analysis was utilized to analyze the data obtained 
from the depth and area of fluorescence measurements (which were all background 
subtracted).  To compare the relative depth of fluorescence between groups; the higher 
pressure OPI device, the standard pressure OPI device [22], the standard treatment group 
(where no OPI device employed to apply the Metvix® cream) [22] and the combined OPI 
measurements, these data were analyzed using the non-parametric Mann Whitney U test.  
10 
 
Combined OPI measurements were subsequently employed to increase the numbers of data 
points for statistical comparison. 
 
3. Results 
 
3.1.    Fluorescence microscopy 
All 15 tissue samples were analyzed and their data are included as a whole in Table 1, 
however for brevity, not all samples are illustrated in Figure 2.  Fig. 2a-e therefore presents 
typical fluorescence micrographs (and the corresponding H and E images) of nBCC tissue 
sections excised at 0, 30, 60, 120 or 180 minutes respectively after the application of 
Metvix® and the OPI device.  For each fluorescence image the arrow indicates the depth of 
maximum fluorescence observed from the surface of the tumor and for each H and E stained 
image the arrow indicates the maximal tumor depth from its surface. 
Fig. 2a shows a typical nBCC lesion without Metvix® application (control) and 
demonstrates no visible PpIX fluorescence.  This can be attributed to the fact that without 
exogenous administration of MAL, no detectable levels of endogenous PpIX accumulated 
within cells of either the tumor or the surrounding normal tissue.  Fig. 2b-e show the 
distribution of MAL-induced PpIX fluorescence in nBCC lesions 30, 60, 120 or 180 minutes 
respectively after application of Metvix® with the OPI device.  In each case, fluorescence 
can be observed in the epidermis overlying the tumor as well as in at least some of the tumor 
cells.  Notable fluorescence was observed 180 minutes following Metvix® application with 
OPI (Fig. 2e), which is the length of the standard drug-light interval employed in 
dermatological MAL-PDT [28].  However at this time point the fluorescence observed still 
failed to achieve full thickness penetration of the tumors to be treated, highlighting the 
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difficulties experienced clinically when trying to treat these thicker NMSC with the current 
topical PDT regime. 
 
3.2. Depth and area of PpIX distribution 
For each tissue sample, without knowing the treatment group the maximum depth of 
fluorescence observed was measured as well as the corresponding maximum tumor depth of 
the H and E section.  Table 1 shows the maximum depth of each nBCC analyzed and a 
median value for each time group.  The range of depth of the lesions investigated varied 
greatly (470.3 to 2011.8 µm) demonstrating a high interpatient variability.  The range of 
depth of PpIX penetration varied from 0 to 1150.8 µm and the median values for each group 
increased over time; when the Metvix® cream was applied for 0, 30, 60, 120 and 180 
minutes the median depth of PpIX fluorescence was 0, 150.5, 303.8, 741.8 and 1016.7 µm, 
respectively.  One example of the variation between patients occurred most markedly in 
patient 12 (Metvix® for 2 hours), in which the depth of PpIX fluorescence exceeded that of 
the nBCC depth measured.  This only occurred in patient 12 and was due to the detection of 
PpIX fluorescence within a sebaceous gland which can act as a route of PpIX penetration. 
A percentage of depth of PpIX penetration was then calculated (Fig. 3) to try and 
minimize the effect of the heterogeneous nature of nBCC tumors.  In addition, the total area 
of fluorescence and the total area of tumor were measured and a percentage of PpIX 
accumulation in relation to the tumor size calculated (Fig. 4).  Fig. 3 demonstrates that as 
expected there is a strong correlation between relative depth of fluorescence observed in the 
tumors and Metvix® application time (R2 = 0.962).  The same trend was observed when the 
relative area of fluorescence was examined (Fig. 4), with a strong correlation between 
relative area of fluorescence observed in the tumors and Metvix® application time was also 
being detected (R2 = 0.824).  In this study fluorescence of the full tumor thickness and 
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fluorescence of the full tumor area of these nBCC lesions was not always reached suggesting 
more than one treatment cycle would be required to effectively treat these thicker tumours.   
Comparison of the results presented here with those published previously [20] revealed 
the same trends (Fig. 5), however the differences observed between the new higher pressure 
OPI device and the previously published standard treatment (no OPI) data [20] were not as 
large as those previously observed with the standard OPI device.  No statistically significant 
difference was observed between the findings observed with the two devices employed 
(p=0.403).  However, combining all the OPI results together (Fig. 5.) did reveal a consistent 
and substantial increase in the depth of PpIX fluorescence observed, although the difference 
between the combined OPI results and the standard treatment (no OPI employed) group did 
not reach significance (p=0.531) in this small sample size. 
 
 
4. Discussion 
 
Topical PDT for nBCC is yet to become an established treatment modality.  Ongoing 
research continues to investigate whether modifications to the standard PpIX-induced PDT 
protocol can be made to increase efficacy.  For example, the use of ALA esters with lower 
lipophilicty such as MAL and HAL, employment of  penetration enhancers such as DMSO 
[29], iron chelation  [30], micro-needle arrays [23], an oxygen pressure injection (OPI) device 
[22], altering light dosimetry parameters [31], modifying oxygen levels [32] and ablative 
fractional laser resurfacing (AFXL) [33]. 
  Previous work has reported the use of a standard pressure oxygen pressure injection 
(OPI) (Oxy-jet®) device in an observer-blinded pilot study of a single application of Metvix® 
to nBCC, with or without the use of OPI.  At different time intervals (0-180 minutes) the 
tumors were excised and depth of penetration of MAL was measured using fluorescence 
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microscopy to detect the production of PpIX.  The results suggested two things, firstly using 
the OPI device may reduce the time required between cream application and light treatment 
and secondly by using OPI the prodrug MAL may penetrate deeper into thicker tumors [22].  
In this study, employing a more powerful higher pressure machine, increasing the penetration 
of MAL was the ultimate goal.  Once again a definite trend of increased relative depth of 
MAL-induced PpIX with increased application time was observed, and this appeared to be 
slightly enhanced compared to the relative depths of MAL-induced PpIX recorded in the 
previous study when no OPI device was employed.  However, when comparing the two 
different OPI devices, no significant difference in MAL-induced PpIX penetration was 
observed (p=0.403), with the small sample size employed.  This suggests either device could 
be incorporated into MAL-PDT protocols to deliver the same beneficial effects of increased 
MAL penetration.  However at the licensed MAL-PDT protocol drug-light interval of 180 
minutes full tumor thickness fluorescence was not observed in all cases.  This indicates that it 
is likely that, if maximal efficacy is desired, the drug-light interval cannot be reduced and 
more than one treatment cycle is required to treat these nodular tumors.  The application of 
OPI after Metvix® application however is a simple and fast treatment modification, with the 
disposable and autoclavable nozzle dome being large enough to treat the majority of single 
nBCC lesions recruited for PpIX-induced PDT whilst still remaining small enough to be easy 
to position over the majority of lesions. 
Noteworthy as a limitation of this study was that despite being blinded to the study 
group identifications during the analysis, only a single user analysed the tissue slices.   
Furthermore, thirteen patients are represented in each scatter diagram (Fig. 3 and Fig. 4) not 
15, as originally recruited into each group, as the tissue section available for analysis from 
patient 8 was folded on the slide and difficult to interpret and the tissue section from patient 
11 was accidentally photobleached prior to analysis.  Finally, as this study investigated a 
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small number of patients in each group, minimal statistical analysis was conducted.  To get a 
better understanding of the results and to inform the development of a future clinical trial 
more data is needed by sampling a greater number of patients.   
In another recent study investigating PpIX fluorescence enhancement [34] the skin of 
14 healthy volunteers was pre-treated with micro-needles prior to the application of 2%, 8% 
and 16% MAL for 4 hours.  The results from this study are promising – following incubation 
the use of micro-needles increased PpIX fluorescence with 2% and 8% MAL but not with 
16%.   
The results presented here and the previous study with the OPI device [22], although 
limited, are encouraging.  The simple technique of employing pressurized oxygen may be a 
useful modification to the standard topical MAL-PDT protocol.  No discomfort was felt by 
any patient upon application of the OPI device and no adverse affects from the trial were 
reported.  Future studies should consider the efficacy of treatment of nBCC with the use of an 
OPI device at time of Metvix® application followed by the standard PDT procedure (a three 
hour time lapse prior to light activation with visible red light (635 nm)) with clinical outcome 
assessments made at follow-up appointments of at least 3, 6, 12 and 24 months.  Furthermore, 
the licensed MAL-PDT treatment for superficial BCC and Bowen’s disease requires two 
treatment cycles.  These lesion types may therefore also benefit from the use of an OPI 
device to enhance penetration of MAL if a single treatment cycle would be preferable and so 
future OPI studies could also consider the best protocol for these lesion types. 
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Table 1.  Maximum depth of each nBCC tumor investigated including the median depths 
following Metvix® application with the higher pressure OPI device after 0, 30, 60, 120 and 
180 minutes. 
 
Fig.1.  Photograph of (a) the OPI device (OXY-jet LEO, Nora Bode, Germany) and (b) the 
OXY-jet applicator with the detachable domed nozzle on the end. 
 
Fig.2.  Images of representative nBCC lesions and corresponding haematoxylin and eosin 
sections excised after (a) 0 minutes, (b) 30 minutes, (c) 60 minutes, (d) 120 minutes and (e) 
180 minutes of Metvix® applied with the higher pressure OPI device.  
 
Fig.3. Scatter graph representing the median maximum depth of fluorescence over time for 
each nBCC tumor analyzed (up to 3 hours) (n=13). 
 
Fig.4. Scatter graph representing the median relative area of fluorescence over time for each 
nBCC tumor analyzed (up to 3 hours) (n=13). 
 
Fig.5.  Bar chart representing the median relative depth of fluorescence over time (up to 3 
hours) for Metvix® applied; without an OPI device (standard treatment group), with the 
standard pressure OPI device, with the higher pressure OPI device and the combined results 
observed with Metvix® applied with either the standard or higher pressure OPI device.   
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MAL application 
time (minutes) 
Maximum depth of each nBCC (µm) Group median (µm) 
0 595.8 202.3 1204.0 595.8 
30 507.0 470.3 1000.5 507.0 
60 1144.1 * 1235.0 1189.5 
120 2011.8 ^ 857.1 1434.4 
180 1127.8 1129.2 855.8 1127.8 
* tissue section on slide was folded and difficult to interpret 
^ slide was accidentally photobleached prior to analysis 
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